Abstract: The invention relates to a method for determining the effect of a polymorphism or mutation on the structural properties of a protein wherein the method relies on the structural properties of the protein and so its cleavage during proteolysis.

Abstract: IGF-1 and a hypocaloric amount of nutrient are used to treat a catabolic state in a patient. The IGF-1 and nutrient can be administered simultaneously, separately or sequentially. The amounts of IGF-1 and hypocaloric amount of nutrient are effective for the treatment of the catabolic state.

Abstract: Straight or cyclic pentapeptides with receptor affinity to .mu. or .delta. opioid receptors having a primary sequence backbone of Tyr-X-Phe-Leu-Z, Seq. ID Nos. 1, 2, and 3. X and Z can be covalently coupled to provide a heterocyclic structure according to the following conditions:i) when the pentapeptide is straight X is selected from the group consisting of Ser, Gly, Pro, AMCA and D-Ala and Z is selected from the group consisting of Glu, Gln or amino derivatives of Glu or Gln, Seq. ID No. 1, with the proviso that if X is Ser, then Z is Glu or amino derivatives of Glu; andii) where the pentapeptide is cyclic X is selected from the group consisting of D- or L-2,4-diaminobutyric acid, D- or L-lysine, D- or L-ornithine and D or L-cysteine and Z is selected from the group consisting of Gln or Glu or amino derivatives of Gln or Glu, Seq. ID No. 2, and 3, with the proviso that if X is D-or L-Cys, then Z is Cys, Seq. ID No. 3.

Abstract: A liquid preparation of a pharmaceutically active agent having a defined composation is repeatedly dosed from a multi-dose container having a defined volume. The amount dosed is selected as 1/N of the volume of the multi-dose container, N being an integer having a value of 2 or higher.A device for dosing a liquid preparation comprises a holder (1) for a multi-dose container (2), which has a movable rear wall (5) acting as a piston for expelling the liquid preparation (6) from the container, and a piston rod (7), which is provided with releasable blocking means (11, 14, 19, 22), such that the movement of the piston rod is limited to a preset length (35) corresponding to an expelled volume of 1/N of the volume of said multi-dose container, N being an integer having a value of 2 or higher.A preferred embodiment of the device is as an injection device for repeated parenteral injections from an injection cartridge.

Abstract: The present invention provides an O-Glycosylated Insulin-like Growth Factor 1 (IGF-1) analog of Insulin-like Growth Factor 1, a seventy amino acids single polypeptide chain which displays relatively high homology with proinsulin, essentially free from unglycosylated IGF-1.

Abstract: A method for improving the regeneration of transected peripheral nerves in mammals and man, by administering a sufficient amount of insulin-like growth factor 1 (IGF-1) to a mammalian host in need of such treatment. If desired, administration of the medicament containing insulin like growth factor can be carried out locally by infusion.

Abstract: A dual-chamber cylinder ampoule is used for the mixture of a sensitive, solid medicament, with liquid which is caused to flow calmly through the medicament in order to avoid any shaking and mechanical influence. The mixing is preferably carried out at a pressure above atmospheric.An injection device for the preparation of an injection solution and a following injection of such solution includes first and second tubular members for enclosing and holding a dual-chamber cylinder ampoule, in which the dry medicament is kept separated from the liquid. When the two tubular members are being screwed together the liquid is calmly and gently mixed with the dry medicament and dissolves it, and the resulted solution can thereafter be injected by means of the dosage and administration mechanism, provided in one tubular member, through a needle arranged at the front end of the other tubular member.

Abstract: The application discloses (A) a growth-promoting polypeptide having molecular weight from about 5,000 to about 7,000 chromatographic mobility under electrophoresis from about 0.25 to about 0.37 relative to lysine at pH 5 and from about 0.17 to about 0.43 relative to aspartic acid at pH 7.5, terminal amino acid at its amino end being asparagine or aspartic acid, and respective amounts of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, leucine, tyrosine, phenylalanine, lysine, arginine, trypophan, and cysteine or carboxymethyl cysteine, and also a couple of instances also methionine, isoleucine and histidine; and (B) the derivation of the polypeptides from blood serum or plasma or a plasma fraction by combined steps of (a) homogenizing the starting material in water, (b) admixing a solution of hydrochloric acid in ethanol thereby splitting the polypeptide from its carrier proteins and precipitating them, (c) adjusting the pH to 8.